Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can 'Microdosing' mindfulness ease long COVID's emotional toll?

NCT ID NCT05676008

Symptom relief Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a short, online mindfulness program for people still suffering from long COVID symptoms like brain fog, fatigue, and pain. The program includes four training sessions and daily 'microdoses' of mindfulness activities. Researchers want to see if this approach can improve well-being and reduce stress, anxiety, and depression in 400 participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
microdosing of mindfulness (behavioral intervention)
What this could lead to
If it works, this could offer a simple, drug-free way to help people with long COVID feel better emotionally and cope with ongoing symptoms.
What could go wrong
This is an early-stage behavioral study with no blinding or placebo control, so results may be influenced by participant expectations. The intervention is brief and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2023

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to participate in online zoom sessions and complete online surveys for 3 months * English speakers * Had a mild to moderate in severity COVID-19 infection \> 3 months ago, feeling unwell, and are still experiencing in the present at least one PASC-related symptoms: * Coughing or feeling short of breath * Loss of smell or change in taste * Recurrent Fever * Body aches, headaches, chest pain, or stomach pain * Brain fog (feeling like you can't think clearly) * Having trouble sleeping * Feeling very tired * Mood changes Exclusion Criteria: * Adults that were admitted to an intensive care unit or placed on a respirator, had invasive heart (heart catheterization) or lung tests (bronchoscopy) performed. * Prisoners

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post-acute COVID-19 syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post-acute COVID-19 syndrome

Contacts and locations

Locations

  • University of California Davis

    Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.